Friday the 13^th could be a make-or-break day in the U.S. for Intercept Pharmaceuticals Inc.’s Ocaliva (obeticholic acid). That’s the day the company will make its case before the FDA’s Gastrointestinal Drugs Advisory Committee for turning an 8-year-old accelerated approval into traditional approval.

Criminal and civil charges related to insider trading were filed Sept. 10 against Dishant Gupta based on his stock purchases of Epizyme Inc. in the months leading up to its acquisition by Ipsen SA.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abacus, Alimera, Alopexx, Ani, Bharat, Biogen, C4, Carisma, Genesis, Gilead, Kallyope, KM Biologics, Mirum, Moderna, Novo Nordisk, Osivax, Sanofi, Santhera Pharmaceuticals, Treos, Vir.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Acelyrin, Altimmune, Arrivent, Azafaros, Astrazeneca, Bayer, Boehringer Ingelheim, Corvus, Centessa, Clear Scientific, Daiichi Sankyo, I-Mab, Innovent, Lexicon, Maia, Pliant, Ractigen, Regeneron, Roivant, Sanofi, Stoke, Viridian, Zealand Pharma.

Biopharmas raising money in public or private financings, including: Abvance, Alopexx, Cardiatec, Ionis, MBX, Phoremost.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Aisa, Arrowhead, ARS, Stealth.

New hires and promotions in the biopharma industry, including: Adcentrx, Atara, Enterprise, Haya, Jaguar Health, Khondrion, Pharmazz, Rivus, Torl, Tyra, Versatope.

Another day, another insider trading deal involving biopharma stock. One of the latest U.S. SEC cases involves a retired dentist, Stephen Forlano Sr., who traded on a tip passed on through his son from a close friend who was an analyst at an investment firm handling a strategic financing collaboration with Harmony Biosciences Holdings Inc.